Skip to main content
C

CALIWAY BIOPHARMACEUTICALS CO., LTD. — Investor Relations & Filings

Ticker · 6919 LEI · 984500D2D587B98A7B13 TW Professional, scientific and technical activities
Open in API
Filings indexed 48 across all filing types
Latest filing 2026-04-07 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 6919

About CALIWAY BIOPHARMACEUTICALS CO., LTD.

https://www.caliwaybiopharma.com

Caliway Biopharmaceuticals Co., Ltd. is a clinical-stage company specializing in the discovery and development of small-molecule therapeutics for medical aesthetics and chronic inflammatory diseases. The company focuses on high-value markets with significant unmet medical needs, utilizing unique pharmacological mechanisms to create niche products. Its lead candidate, CBL-514, is a first-in-class injectable drug designed to induce adipocyte apoptosis for non-surgical local fat reduction, cellulite, and the treatment of Dercum’s disease. Other pipeline assets include CBA-539, a long-acting injectable for pigmentation and anti-aging, and CBF-520, which targets central obesity and visceral fat reduction. Caliway aims to redefine aesthetic medicine and inflammatory disease management through innovative, non-invasive treatments that offer improved safety and efficacy over existing therapies.

Recent filings

Filing Released Lang Actions
114年第4季現金流量表
Interim / Quarterly Report Classification · 1% confidence The document is a Consolidated Statement of Cash Flows for Kang-Pai (康霈) for the 4th quarter of 114 (Republic of China calendar). It contains detailed financial data, including comparative figures for the current and previous year, and is provided via the Market Observation Post System (公開資訊觀測站). Since it provides substantive financial statements for a specific interim period (Q4), it is classified as an Interim/Quarterly Report. Q4 2025
2026-04-07 Chinese
114年第4季綜合損益表
Interim / Quarterly Report Classification · 1% confidence The document is a consolidated statement of comprehensive income (financial statement) provided by a company (康霈) for the 4th quarter of the 114th year. It contains detailed financial data, including revenue, costs, expenses, and net profit/loss, rather than just an announcement or a summary. Since it covers a specific quarterly period and provides substantive financial statements, it is classified as an Interim/Quarterly Report. Q4 2025
2026-04-07 Chinese
114年第4季資產負債表
Interim / Quarterly Report Classification · 1% confidence The document is a Consolidated Balance Sheet (合併資產負債表) provided by a company (康霈) for the 4th quarter of the 114th year (Republic of China calendar). It contains detailed financial data including assets, liabilities, and equity. Since it provides substantive financial statements for a specific quarterly period, it is classified as an Interim/Quarterly Report (IR). Q4 2025
2026-04-07 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.